Naturally Occurring Deletions/Insertions in HBV Core Promoter Tend to Decrease in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients during Antiviral Therapy

Abstract

Background

Mutations in HBV core promoter (CP) are suggested to affect viral replication and disease progression. We investigated CP deletion/insertion mutations (Del/Ins) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients before and during antiviral treatment.

Methods

Direct and clone sequencings were used for detection of CP Del/Ins in 12 patients. The dynamic changes of CP Del/Ins were tracked in these cases until week 48 of treatment. The effects of Del/Ins on CP activities and hepatitis B X protein (HBx) were analysed using luciferase assay and sequence comparison, respectively. Furthermore, 292 untreated HBeAg-positive CHB cases were also analysed.

Results

Twelve cases with multi-peak PCR direct sequencing electropherograms at baseline were con-firmed to have CP Del/Ins by clone sequencing, with detection rates varying from 14.8% to 93.3% of clones analysed. Follow-up studies showed the detection rates of CP Del/Ins in patients decreased from 100% (12/12) at baseline to 16.7% (2/12) at week 48 of treatment (P<0.001), in parallel with a decline in HBV DNA, hepatitis B surface antigen (HBsAg), alanine aminotransferase (ALT) and aspartate transaminase (AST) levels along with an increase in HBeAg loss. Luciferase assay results showed distinct promoter activities among Del/Ins-harbouring CP sequences. Importantly, 71.8% (148/206) of Del/Ins sequences potentially resulted in HBx carboxy-terminal truncations. CP Del/Ins mutations were also found in 27.4% (80/292) of untreated cases.

Conclusions

Naturally occurring complex of CP Del/Ins mutants existed in untreated HBeAg-positive CHB patients. These mutations would affect HBV transcription activities and integrity of HBx, which might correlate with disease progression. Their prevalence decreases on antiviral therapy in parallel with the decline in HBV DNA, HBsAg and ALT and AST levels.

References

Liaw

Y.F.

, Chu

C.M.

Hepatitis B virus infection.

Lancet 2009; 373: 582–592.

, Fan

, Hou

Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China.

Front Med 2014; 8: 135–144.

Chotiyaputta

, Lok

A.S.

Hepatitis B virus variants.

Nat Rev Gastroenterol Hepatol 2009; 6: 453–462.

Quarleri

Core promoter: a critical region where the hepatitis B virus makes decisions.

World J Gastroenterol 2014; 20: 425–435.

Muñoz

, Chen

J.G.

, Egner

P.A.

Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China.

Carcinogenesis 2011; 32: 860–865.

, Ren

, Liu

Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure.

J Gastroenterol 2011; 46: 391–400.

Scaglioni

P.P.

, Melegari

, Wands

J.R.

Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame.

Virology 1997; 233: 374–381.

, Zhou

, Wang

, Qiao

Hepatitis B virus-induced hepatocellular carcinoma.

Cancer Lett 2014; 345: 216–222.

Lin

C.L.

, Liao

L.Y.

, Wang

C.S.

Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.

Liver Int 2004; 24: 9–15.

10.

Chen

C.H.

, Lee

C.M.

, Lu

S.N.

Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.

J Hepatol 2006; 44: 76–82.

11.

Fang

, Teng

, Xu

W.Z.

Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C.

J Med Virol 2009; 81: 826–835.

12.

Chen

S.J.

, Zhao

Y.X.

, Fang

Viral deletions among healthy young Chinese adults with occult hepatitis B virus infection.

Virus Res 2012; 163: 197–201.

13.

Chen

W.N.

, Oon

C.J.

Mutations and deletions in core promoter and precore stop codon in relation to viral replication and liver damage in Singaporean hepatitis B virus carriers.

Eur J Clin Invest 2000; 30: 787–792.

14.

Laskus

, Radkowski

, Nowicki

, Wang

L.F.

, Vargas

, Rakela

Association between hepatitis B virus core promoter rearrangements and hepatocellular carcinoma.

Biochem Biophys Res Commun 1998; 244: 812–814.

15.

Preikschat

, Gunther

, Reinhold

Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients.

Hepatology 2002; 35: 466–477.

16.

Fujiwara

, Tanaka

, Paulon

Novel type of hepatitis B virus mutation: replacement mutation involving a hepatocyte nuclear factor 1 binding site tandem repeat in chronic hepatitis B virus genotype E.

J Virol 2005; 79: 14404–14410.

17.

Zoulim

, Locarnini

Hepatitis B virus resistance to nucleos(t)ide analogues.

Gastroenterology 2009; 137: 1593–1608.

18.

EASL Clinical Practice Guidelines.

Management of chronic hepatitis B.

J Hepatol 2009; 50: 227–242.

19.

Liu

B.M.

, Li

, Xu

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients.

Antiviral Res 2010; 85: 512–519.

20.

Yan

C.H.

, Zhao

C.Y.

, Ding

Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients.

Antiviral Res 2012; 96: 108–114.

21.

Günther

, Li

B.C.

, Miska

, Kruger

D.H.

, Meisel

, Will

A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients.

J Virol 1995; 69: 5437–5444.

22.

Chen

I.H.

, Huang

C.J.

, Ting

L P.

Overlapping initiator and TATA box functions in the basal core promoter of hepatitis B virus.

J Virol 1995; 69: 3647–3657.

23.

Hammock

E.A.

, Young

L.J.

Microsatellite instability generates diversity in brain and sociobehavioral traits.

Science 2005; 308: 1630–1634.

24.

Bernard

H.U.

Regulatory elements in the viral genome.

Virology 2013; 445: 197–204.

25.

Yang

H.I.

, Yeh

S.H.

, Chen

P.J.

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.

J Natl Cancer Inst 2008; 100: 1134–1143.

26.

Lee

M.H.

, Yang

H.I.

, Liu

Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.

Hepatology 2013; 58: 546–554.

27.

Iloeje

U.H.

, Yang

H.I.

, Su

, Jen

C.L.

, You

S.L.

, Chen

C.J.

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

Gastroenterology 2006; 130: 678–686.

28.

Günther

, Piwon

, Iwanska

, Schilling

, Meisel

, Will

Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease.

J Virol 1996; 70: 8318–8331.

29.

Sze

K.M.

, Chu

G.K.

, Lee

J.M.

, Ng

I.O.

C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma.

Hepatology 2013; 57: 131–139.

30.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B.

Hepatology 2007; 45: 507–539.

31.

Liaw

Y.F.

, Leung

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Hepatol Int 2008; 2: 263–283.